26/05/2026
RPI 2890
Notificação de oposição
IPAS423
Petições de oposição: 850260206469 de 01/05/2026
Voltar para busca
Brasil501883513
MYOFORMIN
Emmyon, Inc.
Aguardando manifestação sobre oposiçãoClasse 5Verbal
Andamento no INPI
Exigência a cumprir- Depósito16/09/25
O INPI fez uma exigência formal neste pedido. Enquanto não for cumprida, o processo não avança.
Última movimentação publicada pelo INPI: 26/05/2026. Atualizamos a cada nova RPI, publicada semanalmente.
Classificação técnica
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medicationspharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications or conditions or complications associated with any of the foregoingnutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medicationsnutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength
Publicações
Histórico de despachos e eventos da marca no INPI.
2 publicações encontradas
03/03/2026
RPI 2878
Publicação de pedido de registro para oposição (exame formal de designação concluído)
IPAS756